Diabetic Neuropathy Treatment Market Share Report, 2032

Diabetic Neuropathy Treatment Market – By Disease Type (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy), Treatment (Drug Class [Antidepressant], Radiotherapy and Physiotherapy), Distribution Channel, Forecast, 2024 - 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definitions

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3.1&nbsp;&nbsp;&nbsp; Base year calculation

1.3.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.4&nbsp;&nbsp;&nbsp; Forecast model

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.5.2&nbsp;&nbsp;&nbsp; Data mining sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Increasing prevalence of diabetes

3.2.1.2&nbsp;&nbsp;&nbsp; Advancements in therapeutic and diagnostic techniques

3.2.1.3&nbsp;&nbsp;&nbsp; Rising awareness about diabetic complications

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp; High costs of treatment

3.2.2.2&nbsp;&nbsp;&nbsp; Availability of alternative therapies

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape

3.5&nbsp;&nbsp;&nbsp; Reimbursement scenario

3.6&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.7&nbsp;&nbsp;&nbsp; PESTEL analysis

3.8&nbsp;&nbsp;&nbsp; Future market trends

3.9&nbsp;&nbsp;&nbsp; Gap analysis

3.10&nbsp;&nbsp;&nbsp; Pipeline analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis

4.3&nbsp;&nbsp;&nbsp; Company market share analysis

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp; Strategy dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Disease Type, 2021 &ndash; 2032 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Peripheral neuropathy

5.3&nbsp;&nbsp;&nbsp; Autonomic neuropathy

5.4&nbsp;&nbsp;&nbsp; Proximal neuropathy

5.5&nbsp;&nbsp;&nbsp; Focal neuropathy

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Treatment, 2021 &ndash; 2032 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Drug class

6.2.1&nbsp;&nbsp;&nbsp; Antidepressants

6.2.2&nbsp;&nbsp;&nbsp; Anticonvulsants

6.2.3&nbsp;&nbsp;&nbsp; Non-steroidal anti-inflammatory drugs (NSAIDS)

6.2.4&nbsp;&nbsp;&nbsp; Opioid

6.2.5&nbsp;&nbsp;&nbsp; Other drug classes

6.3&nbsp;&nbsp;&nbsp; Radiotherapy and physiotherapy

6.4&nbsp;&nbsp;&nbsp; Other treatments

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Distribution Channel, 2021 &ndash; 2032 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Hospital pharmacies

7.3&nbsp;&nbsp;&nbsp; Retail pharmacies

7.4&nbsp;&nbsp;&nbsp; Online pharmacies

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 &ndash; 2032 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; North America

8.2.1&nbsp;&nbsp;&nbsp; U.S.

8.2.2&nbsp;&nbsp;&nbsp; Canada

8.3&nbsp;&nbsp;&nbsp; Europe

8.3.1&nbsp;&nbsp;&nbsp; Germany

8.3.2&nbsp;&nbsp;&nbsp; UK

8.3.3&nbsp;&nbsp;&nbsp; France

8.3.4&nbsp;&nbsp;&nbsp; Italy

8.3.5&nbsp;&nbsp;&nbsp; Spain

8.3.6&nbsp;&nbsp;&nbsp; Netherlands

8.3.7&nbsp;&nbsp;&nbsp; Rest of Europe

8.4&nbsp;&nbsp;&nbsp; Asia Pacific

8.4.1&nbsp;&nbsp;&nbsp; China

8.4.2&nbsp;&nbsp;&nbsp; Japan

8.4.3&nbsp;&nbsp;&nbsp; India

8.4.4&nbsp;&nbsp;&nbsp; Australia

8.4.5&nbsp;&nbsp;&nbsp; South Korea

8.4.6&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

8.5&nbsp;&nbsp;&nbsp; Latin America

8.5.1&nbsp;&nbsp;&nbsp; Brazil

8.5.2&nbsp;&nbsp;&nbsp; Mexico

8.5.3&nbsp;&nbsp;&nbsp; Argentina

8.5.4&nbsp;&nbsp;&nbsp; Rest of Latin America

8.6&nbsp;&nbsp;&nbsp; Middle East and Africa

8.6.1&nbsp;&nbsp;&nbsp; Saudi Arabia

8.6.2&nbsp;&nbsp;&nbsp; South Africa

8.6.3&nbsp;&nbsp;&nbsp; UAE

8.6.4&nbsp;&nbsp;&nbsp; Rest of Middle East and Africa

Chapter 9&nbsp;&nbsp;&nbsp;Company Profiles

9.1&nbsp;&nbsp;&nbsp; Abbott

9.2&nbsp;&nbsp;&nbsp; Boehringer Ingelheim GmbH

9.3&nbsp;&nbsp;&nbsp; Eli Lilly and Company

9.4&nbsp;&nbsp;&nbsp; Glenmark Pharmaceuticals Ltd

9.5&nbsp;&nbsp;&nbsp; Janssen Pharmaceuticals, Inc

9.6&nbsp;&nbsp;&nbsp; Lupin Pharmaceuticals

9.7&nbsp;&nbsp;&nbsp; MEDA Pharma GmBH &amp; Co. KG

9.8&nbsp;&nbsp;&nbsp; Pfizer Inc

&nbsp;&nbsp;&nbsp;

Diabetic Neuropathy Treatment Market

Get a free sample of this report